Ph 3 Trial of MK-3475 (Pembrolizumab) vs Standard Treatment in Recurrent/Metastatic Head and Neck Cancer

Update Il y a 4 ans
Reference: EUCTR2014-001749-26

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To compare the overall survival (OS) in subjects with R/M HNSCC treated with pembrolizumab compared to standard treatment.


Inclusion criteria

  • Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma